ImmunoGen Inc.

558 articles with ImmunoGen Inc.

• ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 01, 2020

  9/1/2020

  ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on August 31, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 79,700 shares of its common stock to five new employees under the ImmunoGen, Inc.

• ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 03, 2020

  8/3/2020

  ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on July 31, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 16,800 shares of its common stock to a new employee under the ImmunoGen, Inc.

• ImmunoGen Reports Recent Progress and Second Quarter 2020 Financial Results

  7/31/2020

  Encouraging Data from FORWARD II Study of Mirvetuximab in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status, Presented at ASCO

• ImmunoGen Announces Webcast of Presentation at Upcoming Canaccord Genuity Virtual Growth Conference

  7/29/2020

  ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming 40th Annual Canaccord Genuity Virtual Growth Conference.

• 

  BioSpace Movers & Shakers, July 24

  7/24/2020

  Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.

• ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 22, 2020

  7/22/2020

  ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that in connection with the appointment of Susan Altschuller, PhD as ImmunoGen’s Senior Vice President and Chief Financial Officer, the compensation committee of ImmunoGen’s Board of Directors granted to Dr. Altschuller non-qualified stock option awards under the ImmunoGen, Inc.

• ImmunoGen Appoints Susan Altschuller, PhD as Senior Vice President and Chief Financial Officer

  7/20/2020

  ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Susan Altschuller, PhD has been appointed Senior Vice President and Chief Financial Officer.

• ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2020 Operating Results

  7/16/2020

  ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, July 31, 2020 to discuss its second quarter operating results.

• ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting

  6/22/2020

  Next Generation FRα-Targeting ADC Engineered to Maximize Potential Clinical Benefit for Patients with Lower FRα Expression Potent Anti-Tumor Activity Exhibited in Ovarian Cancer and Other Tumor Types Regardless of FRα Expression Level

• 

  BioSpace Movers & Shakers, June 5

  6/5/2020

  Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.

• ImmunoGen Announces Virtual 2020 Annual Meeting of Shareholders

  6/3/2020

  ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that the 2020 Annual Meeting of Shareholders (the “Annual Meeting”) will be held virtually due to the public health impact of the coronavirus outbreak (COVID-19) and to support the health and well-being of the Company’s management, shareholders, and other meeting participants.

• ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 02, 2020

  6/2/2020

  ImmunoGen Inc. announced that on May 29, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 98,000 shares of its common stock to three new employees under the ImmunoGen, Inc.

• ImmunoGen Appoints Stacy Coen as Senior Vice President and Chief Business Officer

  6/1/2020

  ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Stacy A. Coen has been appointed Senior Vice President and Chief Business Officer. “We are excited to welcome Stacy to the ImmunoGen leadership team as mirvetuximab soravtansine moves through registration studies and our early-stage pipeline continues to advance,” said

• ImmunoGen Presents Initial Data at ASCO from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status

  5/29/2020

  ImmunoGen Presents Initial Data at ASCO from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin ® in Recurrent Ovarian Cancer, Regardless of Platinum Status With a Confirmed Overall Response Rate of 64% and Favorable Tolerability in Patients with High FRα Expression, Combination Demonstrates Encouraging Outcomes Relative to Available Regimens WALTHAM, Mass.--( BUSINESS WIRE )-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader

• ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference

  5/20/2020

  ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Virtual Healthcare Conference

• ImmunoGen to Present Preclinical Data on IMGN151 at AACR Virtual Annual Meeting

  5/15/2020

  Next Generation Anti-FRα ADC Demonstrates Potent Anti-Tumor Activity in Ovarian Cancer Models and Other FRα-positive Tumor Types in Preclinical Studies

• ImmunoGen Announces Initial Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status

  5/13/2020

  ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced initial data from the FORWARD II study evaluating mirvetuximab soravtansine in combination with Avastin® (bevacizumab) in patients with medium and high folate receptor alpha (FRα)-expressing recurrent ovarian cancer for whom a non-platinum based combination regimen is appropriate.

• ImmunoGen Announces Webcast of Presentation at Upcoming RBC Capital Markets Global Healthcare Virtual Conference

  5/6/2020

  ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming RBC Capital Markets Global Healthcare Virtual Conference.

• ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  5/4/2020

  ImmunoGen Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on April 30, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 38,300 shares of its common stock to two new employees under the ImmunoGen, Inc.

• ImmunoGen Reports Recent Progress and First Quarter 2020 Financial Results

  5/1/2020

  ImmunoGen today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2020.